Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Astellas licenses Theravance gram-positive antibiotic; deal terminated

Executive Summary

To continue building its pipeline of infectious disease therapeutics, Astellas Pharma (created from the merger of Yamanouchi and Fujisawa earlier this year) has licensed worldwide rights (excluding Japan) to develop and commercialize Theravance's telavancin lipoglycopeptide injectable antibiotic for gram-positive infections such as drug-resistant Staphylococcus aureus strains.
Deal Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • R+D and Marketing-Licensing
    • Includes Contract

Related Companies

UsernamePublicRestriction

Register